Clinical Trial

A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 3, 2025 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double blinded, controlled phase I clinical study. To evaluate the safety and immunogenicity of receiving two doses of MVA strain monkeypox attenuated live vaccine in individuals aged 18 years and above.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-08.
Status change: Not Yet Recruiting → Recruiting 2025-10-02
Trial Details
NCT Number NCT06771479
Lead Sponsor Shanghai Institute Of Biological Products
Conditions Monkeypox
Enrollment 120 participants
Start Date 2025-01-22
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-03